Dolutegravir Advocacy Brief

This DTG Advocacy Brief  is developed by women, including young women living with HIV. It explores our rights to ARVs in general, and specifically reflects our voices and concerns over recent measures taken which restrict access to Dolutegravir (DTG), after the issuance of a WHO statement on the subject. Now is the time to reaffirm our commitment to the SDGs and uphold global norms: to support and encourage inclusion in decision making; to address intersecting inequalities facing women in all our diversity; and to commit to ensure our human rights are respected and upheld in our treatment choices.